Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.

Emmanuel Guardiola 1 Delphine Delroeux 2 Bruno Heyd 2 Marielle Combe 3 Veronique Lorgis 1 Martin Demarchi 1 Ulrich Stein 1 Bernard Royer 4, 5 Bruno Chauffert 6 Xavier Pivot 1, 5
1 Service d'oncologie Médicale
2 Service de chirurgie viscérale et digestive - Unité de transplantation hépatique
3 Service d'anesthésie - réanimation
4 Laboratoire de Pharmacologie Clinique et Toxicologie [Besancon]
5 HOTE GREFFON - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
6 CRLCC - CGFL - Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc
Abstract : BACKGROUND: Intra-peritoneal (i.p.) chemotherapy is an encouraging treatment option for ovarian cancer with peritoneum involvement in addition with intravenous (i.v.) chemotherapy. Intra-operative i.p. chemotherapy is an interesting method of administration by enhancing the diffusion of chemotherapy. This study had assessed the feasibility of intra-operative i.p. chemotherapy in patients with peritoneal carcinoma of ovarian cancer. METHODS: From January 2003 to February 2006, 47 patients with stage III ovarian cancer were treated with standard paclitaxel carboplatin intravenous chemotherapy and debulking surgery with intra-operative i.p. chemotherapy. After optimal cytoreductive surgery, defined by no unresectable residual disease > 1 cm, i.p. chemotherapy was performed during surgery. The peritoneal cavity was filled by 3 litres of isotonic saline pre-heated at 37 degrees and 90 mg of cisplatin. The sequence was repeated twice during 2 hours based on previous published studies which optimized the cisplatin dosage and exposure duration. Optimal diffusion was obtained by stirring by hands during the 2 hours. RESULTS: Median age was 59.6 years. No severe haematological or non-haematological toxicity induced by intra operative i.p. chemotherapy was reported. No patient died due to the complications of surgery or the i.p. chemotherapy. No neurotoxicity occurred, and one patients had renal impairment. CONCLUSION: This study demonstrates the feasibility of intra-operative i.p. chemotherapy with cisplatin after optimal resection of peritoneal tumor nodules. Further randomized trials are planned to investigate the clinical benefit of this therapeutic modality.
Type de document :
Article dans une revue
World Journal of Surgical Oncology, BioMed Central, 2009, 7, pp.14. 〈10.1186/1477-7819-7-14〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00484421
Contributeur : Philippe Saas <>
Soumis le : mardi 18 mai 2010 - 14:05:47
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Lien texte intégral

openaccess

Identifiants

Collections

UNIV-FCOMTE | UMR645 | CGFL | FNCLCC

Citation

Emmanuel Guardiola, Delphine Delroeux, Bruno Heyd, Marielle Combe, Veronique Lorgis, et al.. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.. World Journal of Surgical Oncology, BioMed Central, 2009, 7, pp.14. 〈10.1186/1477-7819-7-14〉. 〈inserm-00484421〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

388

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD